


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Scanning electron microscopy of polymeric microparticles, the DDS most 





Figure 2: Illustration of the typical polymeric nanoparticles used for neurodegenerative 
disorder treatment. (A) Nanocapsules, (B) PBCA nanoparticles coated with Tween 80 to 
cross the BBB (C) nanospheres, (D) pegylated nanospheres, (E) nanopheres coated with 






Figure 3: (A) Schematic representation of solid lipid nanoparticles, (B) pegylated solid 





Figure 4: Schematic representation of a typical drug-loaded liposome for brain drug 
delivery 
 
 Figure 5 
 
Figure 5: Schematic representation of a typical polymeric micelle for brain drug 
delivery 
 
 Figure 6 
 
Figure 6: Stereotactic surgery in rats used to administer DDS locally into the brain.  
Table 1. Overview of DDS administered locally for neurodegenerative disorder 
treatment 
 
Disease DDS Drug In vitro In vivo 
Ref 
 
PD PLGA microparticles Carbidopa/levodopa + + [31] 
PD PLGA microspheres Dopamine or norepinephrine + + [32] 
PD PLGA microspheres Non-glycosylated GDNF + + [42, 43] 
PD PLGA microspheres Glycosylated GDNF + + [41, 44] 
PD PLGA-based scaffolds for stem cell therapy NGF and GDNF + + [48, 49] 
PD NESD Dopamine + + [50] 
AD 
 
Polyanhydride sebacic acid copolymer 
microparticles Bethanecol + + [69] 
AD Rods of Ethylene vinyl acetate copolymer (EVAc) NGF + + [80] 
AD PLGA microparticles  NGF + - [86] 
AD PLGA microparticles  NGF + - [87] 
AD PLGA microparticles  NGF + - [88] 
AD PLGA microparticles  NGF - + [89] 
AD PLGA microparticles  NGF + - [91] 
AD PLGA microparticles  NGF - + [90] 
HD PLGA microparticles  NGF + + [121] 
HD Chitosan, PLGA, and alginates microparticles CNTF + - [126] 
HD Particles encapsulating BHK cells of poly (acrylonitrile-co-vinyl chloride) CNTF - + [127] 
HD Particles encapsulating BHK cells of poly (acrylonitrile-co-vinyl chloride)) CNTF - + [128] 
HD Particles encapsulating BHK cells of poly (acrylonitrile-co-vinyl chloride) CNTF - + [129] 
HD Chitosan/PLGA  BDNF + - [130] 
HD 
Protein-loaded lipid implants of PEG and 
glyceryl 
tripalmitate 
(1 mm diameter, 0.8 mm height) 
BDNF + + [131] 
HD Hydrogels (Alginate) VEGF - + [134] 
 
Table 2. Overview of DDS administered systemically for neurodegenerative disorder 
treatment 
 
Disease DDS Drug In vitro In vivo Ref  
PD PBCA nanoparticles NGF + + [51, 52] 
PD PLGA nanoparticles conjugated with a transferring antibody (OX26) Tempol + + [53] 
PD Polyethylenimine/DNA complexes 
Plasmids (yellow fluorescent 
protein-encoding plasmid 
and salmon DNA) 
+ - [55] 
PD Lactoferrin-modified nanoparticles GDNF gene + + [56-58] 
PD Compacted DNA nanoparticles GDNF gene + + [59] 
PD Amino-functionalized organically modified silica (ORMOSIL) Plasmid DNA + - [60, 61] 
PD Pegylated immune liposomes for gene therapy TH expression plasmid + + [62] 
PD Liposomes Dopamine + + [6] 
AD Microemulsion Tacrine + + [93] 
AD Chitosan microparticles  Tacrine + + [94] 
AD Poly (n-butylcyanocrylate) nanoparticles Rivastigmine + + [96] 
AD Single-walled carbon nanotubes Acetylcholine + + [101] 
AD PLGA microparticles  Aβ(1-42) peptide + + [102] 
AD PLGA microparticles  
Aβ(1-42) 
Aβ (1–12) 
Aβ (29–40) peptides 
+ + [103] 
AD Chitosan nanoparticles  Aβ(1-42) peptide + + [106] 
AD Liposomes Palmitoylated Aβ(1–16) peptides + + [107] 
AD Liposomes 
Tetra-palmitoylated Aβ (1-
15) peptide, Aβ (1-16) 
peptide linked to a 
polyethyleneglycol 
+ + [108] 
AD Nanogels (cholesterol-bearing pullulan) Artificial chaperones + - [109] 
 
 
 
